Dr. Devon Mckenzie, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
2500 English Creek Ave Bldg 4002nd
Egg Harbor Township, NJ 08234
Who else practices at this address →
Atlantic County is a federal mental health shortage area; it also includes primary care (16% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 356
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NJ license 25MA10541600 -
Internal Medicine Physician
NY license NIL
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Atlanticare Regional Medical Center - City Campus Atlantic City, NJ
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 356
- Services billed
- 805
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 322 | 168 |
| Established patient office or other outpatient visit, 40-54 minutes | 204 | 80 |
| Established patient office or other outpatient visit, 20-29 minutes | 117 | 94 |
| New patient office or other outpatient visit, 45-59 minutes | 46 | 46 |
| New patient office or other outpatient visit, 60-74 minutes | 37 | 37 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 35 | 35 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 29 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 73 |
| Prednisone Other prescribers in Egg Harbor Township, NJ | 25 |
| Abiraterone Acetate | 17 |
| Letrozole Other prescribers in Egg Harbor Township, NJ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 35 companies reported 123 payments worth $8,896 in total to this clinician.
| Pfizer Inc. | $6,704 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $381 |
| AstraZeneca Pharmaceuticals LP | $184 |
| Novartis Pharmaceuticals Corporation | $177 |
| Dendreon Pharmaceuticals LLC | $125 |
| Janssen Biotech, Inc. | $99.46 |
| GlaxoSmithKline, LLC. | $93.18 |
| Celgene Corporation | $80.92 |
| Consulting Fee | $6,480 |
|---|---|
| Food and Beverage | $2,416 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 13, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $5,040 |
| Pfizer Inc. Oct 3, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $1,440 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $124,508 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized openlabel study of PF06821497 mevrometostat in combination with enzalutamide compared with enzalutamide or docetaxel in participants with metastatic castration resistant prostate cancer previously…
Pfizer Inc. - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.